nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—ADRB2—prostate cancer	0.724	1	CbGaD
Metipranolol—Acebutolol—SLC22A1—prostate cancer	0.000986	0.142	CrCbGaD
Metipranolol—Esmolol—ADRB2—prostate cancer	0.000781	0.112	CrCbGaD
Metipranolol—Atenolol—ADRB2—prostate cancer	0.000681	0.0978	CrCbGaD
Metipranolol—Tension—Goserelin—prostate cancer	0.000634	0.00249	CcSEcCtD
Metipranolol—Asthenia—Cabazitaxel—prostate cancer	0.000634	0.00249	CcSEcCtD
Metipranolol—Acebutolol—ADRB2—prostate cancer	0.000629	0.0903	CrCbGaD
Metipranolol—Tension—Conjugated Estrogens—prostate cancer	0.000628	0.00247	CcSEcCtD
Metipranolol—Nervousness—Goserelin—prostate cancer	0.000628	0.00247	CcSEcCtD
Metipranolol—Oxprenolol—ADRB2—prostate cancer	0.000624	0.0896	CrCbGaD
Metipranolol—Nausea—Nilutamide—prostate cancer	0.000624	0.00245	CcSEcCtD
Metipranolol—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000622	0.00245	CcSEcCtD
Metipranolol—Nervousness—Conjugated Estrogens—prostate cancer	0.000622	0.00244	CcSEcCtD
Metipranolol—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000622	0.00244	CcSEcCtD
Metipranolol—Nausea—Flutamide—prostate cancer	0.000621	0.00244	CcSEcCtD
Metipranolol—Dizziness—Degarelix—prostate cancer	0.00062	0.00244	CcSEcCtD
Metipranolol—Epistaxis—Estradiol—prostate cancer	0.000618	0.00243	CcSEcCtD
Metipranolol—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000618	0.00243	CcSEcCtD
Metipranolol—Vision blurred—Goserelin—prostate cancer	0.000609	0.00239	CcSEcCtD
Metipranolol—Vision blurred—Conjugated Estrogens—prostate cancer	0.000603	0.00237	CcSEcCtD
Metipranolol—Acute coronary syndrome—Mitoxantrone—prostate cancer	0.000602	0.00237	CcSEcCtD
Metipranolol—Myocardial infarction—Mitoxantrone—prostate cancer	0.000599	0.00235	CcSEcCtD
Metipranolol—Conjunctivitis—Mitoxantrone—prostate cancer	0.000594	0.00233	CcSEcCtD
Metipranolol—Rash—Degarelix—prostate cancer	0.000591	0.00232	CcSEcCtD
Metipranolol—Dermatitis—Degarelix—prostate cancer	0.000591	0.00232	CcSEcCtD
Metipranolol—Rhinitis—Estradiol—prostate cancer	0.00059	0.00232	CcSEcCtD
Metipranolol—Headache—Degarelix—prostate cancer	0.000588	0.00231	CcSEcCtD
Metipranolol—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000586	0.0023	CcSEcCtD
Metipranolol—Dizziness—Cabazitaxel—prostate cancer	0.000584	0.0023	CcSEcCtD
Metipranolol—Atrial fibrillation—Docetaxel—prostate cancer	0.000578	0.00227	CcSEcCtD
Metipranolol—Alprenolol—ADRB2—prostate cancer	0.000571	0.082	CrCbGaD
Metipranolol—Palpitations—Goserelin—prostate cancer	0.000571	0.00224	CcSEcCtD
Metipranolol—Visual impairment—Estradiol—prostate cancer	0.000567	0.00223	CcSEcCtD
Metipranolol—Palpitations—Conjugated Estrogens—prostate cancer	0.000566	0.00222	CcSEcCtD
Metipranolol—Cough—Goserelin—prostate cancer	0.000564	0.00222	CcSEcCtD
Metipranolol—Atrial fibrillation—Capecitabine—prostate cancer	0.00056	0.0022	CcSEcCtD
Metipranolol—Hypersensitivity—Bicalutamide—prostate cancer	0.000559	0.0022	CcSEcCtD
Metipranolol—Cough—Conjugated Estrogens—prostate cancer	0.000558	0.0022	CcSEcCtD
Metipranolol—Bradycardia—Mitoxantrone—prostate cancer	0.000558	0.00219	CcSEcCtD
Metipranolol—Hypertension—Goserelin—prostate cancer	0.000558	0.00219	CcSEcCtD
Metipranolol—Nausea—Degarelix—prostate cancer	0.000557	0.00219	CcSEcCtD
Metipranolol—Headache—Cabazitaxel—prostate cancer	0.000554	0.00218	CcSEcCtD
Metipranolol—Lacrimation increased—Epirubicin—prostate cancer	0.000552	0.00217	CcSEcCtD
Metipranolol—Myalgia—Goserelin—prostate cancer	0.00055	0.00216	CcSEcCtD
Metipranolol—Rhinitis—Mitoxantrone—prostate cancer	0.00055	0.00216	CcSEcCtD
Metipranolol—Anxiety—Goserelin—prostate cancer	0.000548	0.00215	CcSEcCtD
Metipranolol—Arthritis—Capecitabine—prostate cancer	0.000546	0.00215	CcSEcCtD
Metipranolol—Myalgia—Conjugated Estrogens—prostate cancer	0.000545	0.00214	CcSEcCtD
Metipranolol—Asthenia—Bicalutamide—prostate cancer	0.000544	0.00214	CcSEcCtD
Metipranolol—Discomfort—Goserelin—prostate cancer	0.000543	0.00214	CcSEcCtD
Metipranolol—Anxiety—Conjugated Estrogens—prostate cancer	0.000543	0.00213	CcSEcCtD
Metipranolol—Metoprolol—ADRB2—prostate cancer	0.000531	0.0762	CrCbGaD
Metipranolol—Oedema—Goserelin—prostate cancer	0.000527	0.00207	CcSEcCtD
Metipranolol—Nausea—Cabazitaxel—prostate cancer	0.000525	0.00206	CcSEcCtD
Metipranolol—Oedema—Conjugated Estrogens—prostate cancer	0.000522	0.00205	CcSEcCtD
Metipranolol—Lacrimation increased—Doxorubicin—prostate cancer	0.000511	0.00201	CcSEcCtD
Metipranolol—Tension—Estradiol—prostate cancer	0.000503	0.00198	CcSEcCtD
Metipranolol—Dizziness—Bicalutamide—prostate cancer	0.000501	0.00197	CcSEcCtD
Metipranolol—Acute coronary syndrome—Etoposide—prostate cancer	0.000501	0.00197	CcSEcCtD
Metipranolol—Myocardial infarction—Etoposide—prostate cancer	0.000498	0.00196	CcSEcCtD
Metipranolol—Nervousness—Estradiol—prostate cancer	0.000497	0.00196	CcSEcCtD
Metipranolol—Pindolol—ADRB2—prostate cancer	0.000491	0.0705	CrCbGaD
Metipranolol—Musculoskeletal discomfort—Goserelin—prostate cancer	0.00048	0.00189	CcSEcCtD
Metipranolol—Rash—Bicalutamide—prostate cancer	0.000478	0.00188	CcSEcCtD
Metipranolol—Dermatitis—Bicalutamide—prostate cancer	0.000478	0.00188	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	0.000476	0.00187	CcSEcCtD
Metipranolol—Headache—Bicalutamide—prostate cancer	0.000475	0.00187	CcSEcCtD
Metipranolol—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000472	0.00186	CcSEcCtD
Metipranolol—Dyspnoea—Goserelin—prostate cancer	0.00047	0.00185	CcSEcCtD
Metipranolol—Somnolence—Goserelin—prostate cancer	0.000469	0.00184	CcSEcCtD
Metipranolol—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000466	0.00183	CcSEcCtD
Metipranolol—Somnolence—Conjugated Estrogens—prostate cancer	0.000464	0.00183	CcSEcCtD
Metipranolol—Angina pectoris—Docetaxel—prostate cancer	0.000461	0.00181	CcSEcCtD
Metipranolol—Asthenia—Ethinyl Estradiol—prostate cancer	0.00046	0.00181	CcSEcCtD
Metipranolol—Metoprolol—CYP2C19—prostate cancer	0.000457	0.0656	CrCbGaD
Metipranolol—Palpitations—Estradiol—prostate cancer	0.000453	0.00178	CcSEcCtD
Metipranolol—Nausea—Bicalutamide—prostate cancer	0.00045	0.00177	CcSEcCtD
Metipranolol—Vision blurred—Mitoxantrone—prostate cancer	0.00045	0.00177	CcSEcCtD
Metipranolol—Cough—Estradiol—prostate cancer	0.000447	0.00176	CcSEcCtD
Metipranolol—Angina pectoris—Capecitabine—prostate cancer	0.000447	0.00176	CcSEcCtD
Metipranolol—Abnormal vision—Epirubicin—prostate cancer	0.000444	0.00174	CcSEcCtD
Metipranolol—Hypertension—Estradiol—prostate cancer	0.000442	0.00174	CcSEcCtD
Metipranolol—Bronchitis—Capecitabine—prostate cancer	0.000441	0.00173	CcSEcCtD
Metipranolol—Myalgia—Estradiol—prostate cancer	0.000436	0.00171	CcSEcCtD
Metipranolol—Anxiety—Estradiol—prostate cancer	0.000435	0.00171	CcSEcCtD
Metipranolol—Discomfort—Estradiol—prostate cancer	0.000431	0.00169	CcSEcCtD
Metipranolol—Dizziness—Ethinyl Estradiol—prostate cancer	0.000424	0.00167	CcSEcCtD
Metipranolol—Oedema—Estradiol—prostate cancer	0.000418	0.00164	CcSEcCtD
Metipranolol—Cough—Mitoxantrone—prostate cancer	0.000416	0.00164	CcSEcCtD
Metipranolol—Acute coronary syndrome—Docetaxel—prostate cancer	0.000416	0.00164	CcSEcCtD
Metipranolol—Myocardial infarction—Docetaxel—prostate cancer	0.000414	0.00163	CcSEcCtD
Metipranolol—Hypertension—Mitoxantrone—prostate cancer	0.000412	0.00162	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—prostate cancer	0.000411	0.00161	CcSEcCtD
Metipranolol—Conjunctivitis—Docetaxel—prostate cancer	0.00041	0.00161	CcSEcCtD
Metipranolol—Myalgia—Mitoxantrone—prostate cancer	0.000406	0.0016	CcSEcCtD
Metipranolol—Anxiety—Mitoxantrone—prostate cancer	0.000405	0.00159	CcSEcCtD
Metipranolol—Rash—Ethinyl Estradiol—prostate cancer	0.000404	0.00159	CcSEcCtD
Metipranolol—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000404	0.00159	CcSEcCtD
Metipranolol—Acute coronary syndrome—Capecitabine—prostate cancer	0.000403	0.00158	CcSEcCtD
Metipranolol—Discomfort—Mitoxantrone—prostate cancer	0.000401	0.00158	CcSEcCtD
Metipranolol—Headache—Ethinyl Estradiol—prostate cancer	0.000401	0.00158	CcSEcCtD
Metipranolol—Myocardial infarction—Capecitabine—prostate cancer	0.000401	0.00157	CcSEcCtD
Metipranolol—Epistaxis—Docetaxel—prostate cancer	0.000398	0.00157	CcSEcCtD
Metipranolol—Conjunctivitis—Capecitabine—prostate cancer	0.000397	0.00156	CcSEcCtD
Metipranolol—Oedema—Mitoxantrone—prostate cancer	0.00039	0.00153	CcSEcCtD
Metipranolol—Hypersensitivity—Goserelin—prostate cancer	0.000389	0.00153	CcSEcCtD
Metipranolol—Epistaxis—Capecitabine—prostate cancer	0.000386	0.00152	CcSEcCtD
Metipranolol—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000385	0.00151	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000381	0.0015	CcSEcCtD
Metipranolol—Nausea—Ethinyl Estradiol—prostate cancer	0.000381	0.0015	CcSEcCtD
Metipranolol—Rhinitis—Docetaxel—prostate cancer	0.00038	0.00149	CcSEcCtD
Metipranolol—Asthenia—Goserelin—prostate cancer	0.000378	0.00149	CcSEcCtD
Metipranolol—Asthenia—Conjugated Estrogens—prostate cancer	0.000375	0.00147	CcSEcCtD
Metipranolol—Bradycardia—Capecitabine—prostate cancer	0.000374	0.00147	CcSEcCtD
Metipranolol—Dyspnoea—Estradiol—prostate cancer	0.000373	0.00146	CcSEcCtD
Metipranolol—Somnolence—Estradiol—prostate cancer	0.000372	0.00146	CcSEcCtD
Metipranolol—Rhinitis—Capecitabine—prostate cancer	0.000368	0.00145	CcSEcCtD
Metipranolol—Visual impairment—Docetaxel—prostate cancer	0.000365	0.00144	CcSEcCtD
Metipranolol—Acute coronary syndrome—Prednisone—prostate cancer	0.000359	0.00141	CcSEcCtD
Metipranolol—Myocardial infarction—Prednisone—prostate cancer	0.000357	0.0014	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000355	0.00139	CcSEcCtD
Metipranolol—Visual impairment—Capecitabine—prostate cancer	0.000354	0.00139	CcSEcCtD
Metipranolol—Dizziness—Goserelin—prostate cancer	0.000349	0.00137	CcSEcCtD
Metipranolol—Dyspnoea—Mitoxantrone—prostate cancer	0.000347	0.00136	CcSEcCtD
Metipranolol—Cough—Etoposide—prostate cancer	0.000346	0.00136	CcSEcCtD
Metipranolol—Somnolence—Mitoxantrone—prostate cancer	0.000346	0.00136	CcSEcCtD
Metipranolol—Dizziness—Conjugated Estrogens—prostate cancer	0.000345	0.00136	CcSEcCtD
Metipranolol—Hypertension—Etoposide—prostate cancer	0.000343	0.00135	CcSEcCtD
Metipranolol—Propranolol—CYP3A5—prostate cancer	0.000339	0.0487	CrCbGaD
Metipranolol—Discomfort—Etoposide—prostate cancer	0.000334	0.00131	CcSEcCtD
Metipranolol—Bradycardia—Prednisone—prostate cancer	0.000333	0.00131	CcSEcCtD
Metipranolol—Rash—Goserelin—prostate cancer	0.000332	0.00131	CcSEcCtD
Metipranolol—Dermatitis—Goserelin—prostate cancer	0.000332	0.00131	CcSEcCtD
Metipranolol—Headache—Goserelin—prostate cancer	0.00033	0.0013	CcSEcCtD
Metipranolol—Rash—Conjugated Estrogens—prostate cancer	0.000329	0.00129	CcSEcCtD
Metipranolol—Dermatitis—Conjugated Estrogens—prostate cancer	0.000329	0.00129	CcSEcCtD
Metipranolol—Headache—Conjugated Estrogens—prostate cancer	0.000327	0.00129	CcSEcCtD
Metipranolol—Nausea—Goserelin—prostate cancer	0.000313	0.00123	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—prostate cancer	0.000311	0.00122	CcSEcCtD
Metipranolol—Nausea—Conjugated Estrogens—prostate cancer	0.00031	0.00122	CcSEcCtD
Metipranolol—Hypersensitivity—Estradiol—prostate cancer	0.000308	0.00121	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—prostate cancer	0.000307	0.00121	CcSEcCtD
Metipranolol—Vision blurred—Capecitabine—prostate cancer	0.000301	0.00118	CcSEcCtD
Metipranolol—Asthenia—Estradiol—prostate cancer	0.0003	0.00118	CcSEcCtD
Metipranolol—Palpitations—Docetaxel—prostate cancer	0.000292	0.00115	CcSEcCtD
Metipranolol—Dyspnoea—Etoposide—prostate cancer	0.000289	0.00114	CcSEcCtD
Metipranolol—Somnolence—Etoposide—prostate cancer	0.000288	0.00113	CcSEcCtD
Metipranolol—Cough—Docetaxel—prostate cancer	0.000288	0.00113	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—prostate cancer	0.000288	0.00113	CcSEcCtD
Metipranolol—Hypersensitivity—Mitoxantrone—prostate cancer	0.000287	0.00113	CcSEcCtD
Metipranolol—Hypertension—Docetaxel—prostate cancer	0.000285	0.00112	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—prostate cancer	0.000284	0.00112	CcSEcCtD
Metipranolol—Palpitations—Capecitabine—prostate cancer	0.000282	0.00111	CcSEcCtD
Metipranolol—Myalgia—Docetaxel—prostate cancer	0.000281	0.0011	CcSEcCtD
Metipranolol—Asthenia—Mitoxantrone—prostate cancer	0.000279	0.0011	CcSEcCtD
Metipranolol—Cough—Capecitabine—prostate cancer	0.000279	0.0011	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—prostate cancer	0.000277	0.00109	CcSEcCtD
Metipranolol—Dizziness—Estradiol—prostate cancer	0.000276	0.00109	CcSEcCtD
Metipranolol—Hypertension—Capecitabine—prostate cancer	0.000276	0.00108	CcSEcCtD
Metipranolol—Myalgia—Capecitabine—prostate cancer	0.000272	0.00107	CcSEcCtD
Metipranolol—Anxiety—Capecitabine—prostate cancer	0.000271	0.00107	CcSEcCtD
Metipranolol—Oedema—Docetaxel—prostate cancer	0.000269	0.00106	CcSEcCtD
Metipranolol—Discomfort—Capecitabine—prostate cancer	0.000269	0.00106	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—prostate cancer	0.000269	0.00106	CcSEcCtD
Metipranolol—Vision blurred—Prednisone—prostate cancer	0.000268	0.00105	CcSEcCtD
Metipranolol—Propranolol—ADRB2—prostate cancer	0.000268	0.0385	CrCbGaD
Metipranolol—Rash—Estradiol—prostate cancer	0.000264	0.00104	CcSEcCtD
Metipranolol—Dermatitis—Estradiol—prostate cancer	0.000263	0.00104	CcSEcCtD
Metipranolol—Headache—Estradiol—prostate cancer	0.000262	0.00103	CcSEcCtD
Metipranolol—Oedema—Capecitabine—prostate cancer	0.000261	0.00102	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—prostate cancer	0.00026	0.00102	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—prostate cancer	0.000256	0.00101	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—prostate cancer	0.000256	0.00101	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—prostate cancer	0.000249	0.000977	CcSEcCtD
Metipranolol—Nausea—Estradiol—prostate cancer	0.000248	0.000976	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—prostate cancer	0.000246	0.000968	CcSEcCtD
Metipranolol—Hypertension—Prednisone—prostate cancer	0.000246	0.000966	CcSEcCtD
Metipranolol—Rash—Mitoxantrone—prostate cancer	0.000246	0.000965	CcSEcCtD
Metipranolol—Dermatitis—Mitoxantrone—prostate cancer	0.000245	0.000964	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000245	0.000964	CcSEcCtD
Metipranolol—Headache—Mitoxantrone—prostate cancer	0.000244	0.000959	CcSEcCtD
Metipranolol—Myalgia—Prednisone—prostate cancer	0.000242	0.000952	CcSEcCtD
Metipranolol—Anxiety—Prednisone—prostate cancer	0.000241	0.000949	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—prostate cancer	0.000241	0.000946	CcSEcCtD
Metipranolol—Dyspnoea—Docetaxel—prostate cancer	0.00024	0.000944	CcSEcCtD
Metipranolol—Somnolence—Docetaxel—prostate cancer	0.000239	0.000941	CcSEcCtD
Metipranolol—Discomfort—Prednisone—prostate cancer	0.000239	0.000941	CcSEcCtD
Metipranolol—Hypersensitivity—Etoposide—prostate cancer	0.000239	0.000938	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000238	0.000934	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—prostate cancer	0.000237	0.000932	CcSEcCtD
Metipranolol—Asthenia—Etoposide—prostate cancer	0.000232	0.000914	CcSEcCtD
Metipranolol—Dyspnoea—Capecitabine—prostate cancer	0.000232	0.000914	CcSEcCtD
Metipranolol—Oedema—Prednisone—prostate cancer	0.000232	0.000913	CcSEcCtD
Metipranolol—Nausea—Mitoxantrone—prostate cancer	0.000231	0.000909	CcSEcCtD
Metipranolol—Propranolol—CYP2C19—prostate cancer	0.000231	0.0331	CrCbGaD
Metipranolol—Propranolol—CYP1A1—prostate cancer	0.00023	0.033	CrCbGaD
Metipranolol—Visual impairment—Doxorubicin—prostate cancer	0.000228	0.000896	CcSEcCtD
Metipranolol—Tension—Epirubicin—prostate cancer	0.000218	0.000858	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—prostate cancer	0.000216	0.00085	CcSEcCtD
Metipranolol—Dizziness—Etoposide—prostate cancer	0.000214	0.000842	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000212	0.000832	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—prostate cancer	0.00021	0.000824	CcSEcCtD
Metipranolol—Rash—Etoposide—prostate cancer	0.000204	0.000803	CcSEcCtD
Metipranolol—Dermatitis—Etoposide—prostate cancer	0.000204	0.000802	CcSEcCtD
Metipranolol—Headache—Etoposide—prostate cancer	0.000203	0.000798	CcSEcCtD
Metipranolol—Tension—Doxorubicin—prostate cancer	0.000202	0.000794	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—prostate cancer	0.0002	0.000786	CcSEcCtD
Metipranolol—Hypersensitivity—Docetaxel—prostate cancer	0.000198	0.00078	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—prostate cancer	0.000197	0.000773	CcSEcCtD
Metipranolol—Cough—Epirubicin—prostate cancer	0.000194	0.000763	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—prostate cancer	0.000194	0.000763	CcSEcCtD
Metipranolol—Asthenia—Docetaxel—prostate cancer	0.000193	0.000759	CcSEcCtD
Metipranolol—Nausea—Etoposide—prostate cancer	0.000192	0.000756	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—prostate cancer	0.000192	0.000755	CcSEcCtD
Metipranolol—Hypersensitivity—Capecitabine—prostate cancer	0.000192	0.000755	CcSEcCtD
Metipranolol—Myalgia—Epirubicin—prostate cancer	0.000189	0.000745	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—prostate cancer	0.000189	0.000742	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—prostate cancer	0.000187	0.000736	CcSEcCtD
Metipranolol—Asthenia—Capecitabine—prostate cancer	0.000187	0.000735	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—prostate cancer	0.000182	0.000715	CcSEcCtD
Metipranolol—Oedema—Epirubicin—prostate cancer	0.000182	0.000714	CcSEcCtD
Metipranolol—Cough—Doxorubicin—prostate cancer	0.00018	0.000706	CcSEcCtD
Metipranolol—Dizziness—Docetaxel—prostate cancer	0.000178	0.0007	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—prostate cancer	0.000178	0.000699	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—prostate cancer	0.000175	0.000689	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—prostate cancer	0.000175	0.000687	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—prostate cancer	0.000173	0.000681	CcSEcCtD
Metipranolol—Dizziness—Capecitabine—prostate cancer	0.000172	0.000678	CcSEcCtD
Metipranolol—Hypersensitivity—Prednisone—prostate cancer	0.000171	0.000672	CcSEcCtD
Metipranolol—Rash—Docetaxel—prostate cancer	0.00017	0.000667	CcSEcCtD
Metipranolol—Dermatitis—Docetaxel—prostate cancer	0.00017	0.000667	CcSEcCtD
Metipranolol—Headache—Docetaxel—prostate cancer	0.000169	0.000663	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—prostate cancer	0.000168	0.000661	CcSEcCtD
Metipranolol—Asthenia—Prednisone—prostate cancer	0.000167	0.000655	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000165	0.00065	CcSEcCtD
Metipranolol—Rash—Capecitabine—prostate cancer	0.000164	0.000646	CcSEcCtD
Metipranolol—Dermatitis—Capecitabine—prostate cancer	0.000164	0.000645	CcSEcCtD
Metipranolol—Headache—Capecitabine—prostate cancer	0.000163	0.000642	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—prostate cancer	0.000162	0.000636	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—prostate cancer	0.000161	0.000635	CcSEcCtD
Metipranolol—Nausea—Docetaxel—prostate cancer	0.00016	0.000629	CcSEcCtD
Metipranolol—Nausea—Capecitabine—prostate cancer	0.000155	0.000609	CcSEcCtD
Metipranolol—Dizziness—Prednisone—prostate cancer	0.000154	0.000604	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000153	0.000602	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—prostate cancer	0.00015	0.000589	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—prostate cancer	0.000149	0.000587	CcSEcCtD
Metipranolol—Propranolol—CYP3A4—prostate cancer	0.000147	0.0211	CrCbGaD
Metipranolol—Rash—Prednisone—prostate cancer	0.000146	0.000575	CcSEcCtD
Metipranolol—Dermatitis—Prednisone—prostate cancer	0.000146	0.000575	CcSEcCtD
Metipranolol—Headache—Prednisone—prostate cancer	0.000145	0.000572	CcSEcCtD
Metipranolol—Nausea—Prednisone—prostate cancer	0.000138	0.000542	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—prostate cancer	0.000134	0.000526	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—prostate cancer	0.00013	0.000512	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—prostate cancer	0.000124	0.000487	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—prostate cancer	0.000121	0.000474	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—prostate cancer	0.00012	0.000472	CcSEcCtD
Metipranolol—Rash—Epirubicin—prostate cancer	0.000115	0.00045	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—prostate cancer	0.000114	0.00045	CcSEcCtD
Metipranolol—Headache—Epirubicin—prostate cancer	0.000114	0.000447	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—prostate cancer	0.000111	0.000437	CcSEcCtD
Metipranolol—Nausea—Epirubicin—prostate cancer	0.000108	0.000424	CcSEcCtD
Metipranolol—Rash—Doxorubicin—prostate cancer	0.000106	0.000416	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—prostate cancer	0.000106	0.000416	CcSEcCtD
Metipranolol—Headache—Doxorubicin—prostate cancer	0.000105	0.000414	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—prostate cancer	9.98e-05	0.000392	CcSEcCtD
Metipranolol—ADRB2—Signaling Pathways—MC2R—prostate cancer	1.68e-05	0.00119	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PTHLH—prostate cancer	1.67e-05	0.00118	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PRKACB—prostate cancer	1.63e-05	0.00116	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PTHLH—prostate cancer	1.63e-05	0.00115	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CALCA—prostate cancer	1.62e-05	0.00114	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PRKACB—prostate cancer	1.6e-05	0.00113	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PPP3CA—prostate cancer	1.59e-05	0.00113	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CALCA—prostate cancer	1.58e-05	0.00112	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CXCL12—prostate cancer	1.58e-05	0.00112	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—ANXA1—prostate cancer	1.57e-05	0.00111	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PPP3CA—prostate cancer	1.56e-05	0.0011	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCL12—prostate cancer	1.55e-05	0.00109	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—ANXA1—prostate cancer	1.54e-05	0.00109	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PENK—prostate cancer	1.53e-05	0.00108	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.52e-05	0.00108	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PENK—prostate cancer	1.5e-05	0.00106	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.49e-05	0.00105	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CALCA—prostate cancer	1.47e-05	0.00104	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GHR—prostate cancer	1.46e-05	0.00103	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PRKCQ—prostate cancer	1.44e-05	0.00102	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CALCA—prostate cancer	1.44e-05	0.00102	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCL12—prostate cancer	1.44e-05	0.00102	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GHR—prostate cancer	1.43e-05	0.00101	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PRKCQ—prostate cancer	1.41e-05	0.000998	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCL12—prostate cancer	1.4e-05	0.000993	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NRP1—prostate cancer	1.4e-05	0.00099	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NRP1—prostate cancer	1.37e-05	0.000968	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—ADRB2—prostate cancer	1.36e-05	0.000959	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—VAV3—prostate cancer	1.32e-05	0.000935	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PRKCQ—prostate cancer	1.31e-05	0.000926	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GNRH1—prostate cancer	1.3e-05	0.00092	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VIP—prostate cancer	1.3e-05	0.00092	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—VAV3—prostate cancer	1.29e-05	0.000915	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—ITPR1—prostate cancer	1.28e-05	0.000907	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PRKCQ—prostate cancer	1.28e-05	0.000906	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GNRH1—prostate cancer	1.27e-05	0.0009	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VIP—prostate cancer	1.27e-05	0.0009	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LPAR1—prostate cancer	1.26e-05	0.000891	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GRP—prostate cancer	1.26e-05	0.000891	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—ITPR1—prostate cancer	1.26e-05	0.000887	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PLCB2—prostate cancer	1.25e-05	0.000882	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LRP2—prostate cancer	1.25e-05	0.000882	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LPAR1—prostate cancer	1.23e-05	0.000872	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GRP—prostate cancer	1.23e-05	0.000872	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—ADRB2—prostate cancer	1.23e-05	0.000871	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—P4HB—prostate cancer	1.22e-05	0.000865	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CX3CL1—prostate cancer	1.22e-05	0.000865	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PLCB2—prostate cancer	1.22e-05	0.000863	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LRP2—prostate cancer	1.22e-05	0.000863	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—VAV3—prostate cancer	1.2e-05	0.000849	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIST1H2BG—prostate cancer	1.2e-05	0.000849	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—P4HB—prostate cancer	1.2e-05	0.000846	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CX3CL1—prostate cancer	1.2e-05	0.000846	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GRB7—prostate cancer	1.19e-05	0.000842	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDE4D—prostate cancer	1.19e-05	0.000842	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—VAV3—prostate cancer	1.17e-05	0.000831	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIST1H2BG—prostate cancer	1.17e-05	0.000831	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—ITPR1—prostate cancer	1.17e-05	0.000824	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDE4D—prostate cancer	1.16e-05	0.000823	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GRB7—prostate cancer	1.16e-05	0.000823	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIST1H4H—prostate cancer	1.16e-05	0.00082	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CXCL8—prostate cancer	1.16e-05	0.00082	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—ITPR1—prostate cancer	1.14e-05	0.000806	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIST1H4H—prostate cancer	1.13e-05	0.000802	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CXCL8—prostate cancer	1.13e-05	0.000802	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GNG5—prostate cancer	1.13e-05	0.000801	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GNG5—prostate cancer	1.11e-05	0.000783	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTHLH—prostate cancer	9.86e-06	0.000697	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFBR1—prostate cancer	9.86e-06	0.000697	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKR1C3—prostate cancer	9.7e-06	0.000686	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKACB—prostate cancer	9.65e-06	0.000682	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTHLH—prostate cancer	9.65e-06	0.000682	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFBR1—prostate cancer	9.65e-06	0.000682	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKR1C3—prostate cancer	9.49e-06	0.000671	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKACB—prostate cancer	9.44e-06	0.000668	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PPP3CA—prostate cancer	9.41e-06	0.000665	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—THBS1—prostate cancer	9.41e-06	0.000665	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ANXA1—prostate cancer	9.27e-06	0.000656	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—THBS1—prostate cancer	9.2e-06	0.000651	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PPP3CA—prostate cancer	9.2e-06	0.000651	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCZ—prostate cancer	9.1e-06	0.000644	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ANXA1—prostate cancer	9.07e-06	0.000641	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCZ—prostate cancer	8.9e-06	0.00063	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CG—prostate cancer	8.9e-06	0.000629	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGFR4—prostate cancer	8.79e-06	0.000622	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PARP1—prostate cancer	8.79e-06	0.000622	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CG—prostate cancer	8.7e-06	0.000615	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CALCA—prostate cancer	8.68e-06	0.000614	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGFR4—prostate cancer	8.6e-06	0.000608	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PARP1—prostate cancer	8.6e-06	0.000608	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CALCA—prostate cancer	8.49e-06	0.000601	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL12—prostate cancer	8.48e-06	0.0006	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL12—prostate cancer	8.3e-06	0.000587	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	8.08e-06	0.000571	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP9—prostate cancer	7.99e-06	0.000565	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	7.9e-06	0.000559	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	7.82e-06	0.000553	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP9—prostate cancer	7.81e-06	0.000552	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	7.74e-06	0.000547	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NGFR—prostate cancer	7.74e-06	0.000547	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	7.65e-06	0.000541	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	7.65e-06	0.000541	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	7.57e-06	0.000535	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NGFR—prostate cancer	7.57e-06	0.000535	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	7.48e-06	0.000529	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF10—prostate cancer	7.35e-06	0.00052	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	7.28e-06	0.000515	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF10—prostate cancer	7.19e-06	0.000509	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	7.18e-06	0.000508	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	7.15e-06	0.000506	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	7.1e-06	0.000502	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VAV3—prostate cancer	7.1e-06	0.000502	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	7.02e-06	0.000496	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	6.99e-06	0.000495	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	6.99e-06	0.000495	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	6.95e-06	0.000491	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	6.94e-06	0.000491	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	6.88e-06	0.000487	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	6.84e-06	0.000484	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	6.82e-06	0.000482	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	6.73e-06	0.000476	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	6.67e-06	0.000472	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	6.58e-06	0.000465	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	6.55e-06	0.000463	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	6.52e-06	0.000461	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	6.44e-06	0.000455	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	6.41e-06	0.000453	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	6.38e-06	0.000451	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LPL—prostate cancer	6.31e-06	0.000446	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	6.26e-06	0.000443	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	6.25e-06	0.000442	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	6.19e-06	0.000438	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LPL—prostate cancer	6.17e-06	0.000436	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	6.12e-06	0.000433	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	6.12e-06	0.000432	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	6.09e-06	0.000431	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	6.06e-06	0.000428	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	5.96e-06	0.000421	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	5.95e-06	0.000421	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	5.91e-06	0.000418	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	5.9e-06	0.000417	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	5.82e-06	0.000411	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	5.78e-06	0.000409	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	5.77e-06	0.000408	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	5.69e-06	0.000402	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TERT—prostate cancer	5.66e-06	0.000401	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	5.56e-06	0.000393	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TERT—prostate cancer	5.54e-06	0.000392	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	5.42e-06	0.000383	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	5.3e-06	0.000375	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LEP—prostate cancer	5.29e-06	0.000374	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	5.24e-06	0.00037	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KDR—prostate cancer	5.18e-06	0.000366	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LEP—prostate cancer	5.17e-06	0.000366	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	5.13e-06	0.000362	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KDR—prostate cancer	5.07e-06	0.000358	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	5.05e-06	0.000357	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	4.94e-06	0.000349	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BAD—prostate cancer	4.93e-06	0.000348	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BAD—prostate cancer	4.82e-06	0.000341	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APC—prostate cancer	4.77e-06	0.000337	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	4.77e-06	0.000337	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGF—prostate cancer	4.72e-06	0.000334	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	4.72e-06	0.000334	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	4.67e-06	0.00033	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APC—prostate cancer	4.67e-06	0.00033	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGF—prostate cancer	4.61e-06	0.000326	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	4.61e-06	0.000326	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	4.58e-06	0.000324	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—INS—prostate cancer	4.52e-06	0.000319	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	4.48e-06	0.000317	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	4.43e-06	0.000313	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—INS—prostate cancer	4.42e-06	0.000312	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	4.37e-06	0.000309	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	4.35e-06	0.000307	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	4.33e-06	0.000306	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	4.27e-06	0.000302	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	4.25e-06	0.000301	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	4.22e-06	0.000299	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	4.2e-06	0.000297	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	4.16e-06	0.000294	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	4.15e-06	0.000293	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	4.13e-06	0.000292	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	4.11e-06	0.00029	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	4.1e-06	0.00029	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	4.07e-06	0.000287	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	4.06e-06	0.000287	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	4.02e-06	0.000284	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	4.02e-06	0.000284	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	3.96e-06	0.00028	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	3.93e-06	0.000278	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	3.88e-06	0.000274	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	3.85e-06	0.000272	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	3.77e-06	0.000267	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	3.77e-06	0.000266	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	3.76e-06	0.000266	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	3.71e-06	0.000262	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	3.69e-06	0.000261	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	3.68e-06	0.00026	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	3.66e-06	0.000259	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	3.63e-06	0.000256	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	3.58e-06	0.000253	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	3.51e-06	0.000248	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	3.44e-06	0.000243	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	3.43e-06	0.000243	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	3.39e-06	0.00024	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	3.36e-06	0.000238	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL2—prostate cancer	3.36e-06	0.000237	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	3.36e-06	0.000237	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	3.34e-06	0.000236	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	3.32e-06	0.000235	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	3.29e-06	0.000233	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL2—prostate cancer	3.29e-06	0.000232	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	3.27e-06	0.000232	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	3.27e-06	0.000231	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	3.24e-06	0.000229	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	3.2e-06	0.000226	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	3.18e-06	0.000225	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	3.17e-06	0.000224	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	3.17e-06	0.000224	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	3.16e-06	0.000223	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	3.11e-06	0.00022	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	3.1e-06	0.000219	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	3.09e-06	0.000219	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	3.08e-06	0.000218	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	3.02e-06	0.000213	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EP300—prostate cancer	3.01e-06	0.000213	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EP300—prostate cancer	2.95e-06	0.000208	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SRC—prostate cancer	2.93e-06	0.000207	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SRC—prostate cancer	2.87e-06	0.000203	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	2.85e-06	0.000202	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	2.83e-06	0.0002	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.79e-06	0.000197	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.76e-06	0.000195	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MYC—prostate cancer	2.63e-06	0.000186	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.62e-06	0.000185	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MYC—prostate cancer	2.57e-06	0.000182	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.57e-06	0.000182	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.56e-06	0.000181	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.51e-06	0.000178	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.43e-06	0.000172	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	2.37e-06	0.000168	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.23e-06	0.000158	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	2.18e-06	0.000154	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TP53—prostate cancer	2.16e-06	0.000153	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TP53—prostate cancer	2.11e-06	0.000149	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6—prostate cancer	1.97e-06	0.00014	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6—prostate cancer	1.93e-06	0.000137	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	1.82e-06	0.000129	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.78e-06	0.000126	CbGpPWpGaD
